SAN DIEGO--(BUSINESS WIRE)--Santarus, Inc. (NASDAQ:SNTS) today announced that new data from its Phase III clinical study with the investigational drug rifamycin SV MMX® in patients with travelers’ diarrhea will be featured in a poster presentation at IDWeek™ in San Francisco at the Moscone Center (Poster Hall C) from 12:30 p.m. to 2:00 p.m. Pacific Time on Saturday, October 5, 2013. The poster (#1306) is titled, Randomized, Double-Blind, Placebo-Controlled Study of Rifamycin SV MMX in the Treatment of Travelers’ Diarrhea. IDWeek is the combined annual meeting of the Infectious Diseases Society of America (IDSA), the Society for Healthcare Epidemiology of America (SHEA), the HIV Medicine Association (HIVMA), and the Pediatric Infectious Diseases Society (PIDS).
Help employers find you! Check out all the jobs and post your resume.
